| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Pterin-6-carboxylic acid serves as a precursor for the formation of folate, which plays a critical role in cell growth, development, and repair. Folate is essential for DNA synthesis, methylation, and cellular division. As a folate precursor, Pterin-6-carboxylic acid is involved in the folate biosynthesis pathway. The compound is also a photodegradation product of folate and augments ROS production and phototoxicity of UVA towards human cell lines. Its potential as a fluorescent dye suggests interactions with light and fluorescent properties. The compound's function is related to α-amino acids.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Pterin-6-carboxylic acid augments ROS production and phototoxicity of UVA towards human cell lines. It has been tested against epidermal carcinoma A431, primary melanoma WM115, and keratinocyte HaCaT cells. The compound's potential as a fluorescent dye has been investigated. As a folate precursor, it supports cell growth in folate-dependent cell culture systems. These in vitro findings support its applications in cell biology research, fluorescence imaging, and phototoxicity studies. Further studies are needed to fully characterize its biological activities.
|
| ln Vivo |
In vivo studies of Pterin-6-carboxylic acid are limited, as the compound is primarily used as a research chemical and folate precursor. As a precursor to folate, it is involved in folate metabolism in vivo. The compound's role as a photodegradation product of folate suggests it may be formed in the skin upon UVA exposure. Its potential as a fluorescent dye suggests applications in in vivo imaging. However, comprehensive in vivo pharmacological studies specifically targeting Pterin-6-carboxylic acid as an active pharmaceutical ingredient are not well documented. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Pterin-6-carboxylic acid are not well documented, as the compound is primarily used as a folate precursor and research chemical. Its activity as a folate precursor can be assessed by measuring its conversion to folate in cell-free enzyme systems. The compound's fluorescent properties are characterized using spectrofluorometry. Its ability to augment ROS production is measured using fluorescent ROS probes in cell-free systems. Phototoxicity is assessed by exposing cells or cell-free systems to UVA radiation in the presence of the compound. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Pterin-6-carboxylic acid involve culturing human cell lines to evaluate its effects on ROS production and phototoxicity. Cell lines such as epidermal carcinoma A431, primary melanoma WM115, and keratinocyte HaCaT are treated with the compound and exposed to UVA radiation. ROS production is measured using fluorescent probes such as DCFH-DA. Cell viability is assessed using MTT or similar colorimetric assays. The compound's potential as a fluorescent dye is evaluated using fluorescence microscopy or flow cytometry. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Pterin-6-carboxylic acid are not well documented, as the compound is primarily used as a research chemical and folate precursor. For phototoxicity studies, animals would be treated with the compound and exposed to UVA radiation to assess skin damage. For folate metabolism studies, animals on folate-deficient diets would be supplemented with the compound and folate levels measured. Parameters assessed would include blood folate levels, tissue folate content, and markers of oxidative stress. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Pterin-6-carboxylic acid reflect its nature as a small pterin derivative. It has a molecular weight of 207.15 and the molecular formula C7H5N5O3. The compound has a density of 2.16 g/cm3, a boiling point of 608.7°C, and a melting point of 360°C. It has a LogP of -1.5, indicating high hydrophilicity. The compound has three hydrogen bond donors, six hydrogen bond acceptors, and one rotatable bond. It is soluble in methanol or DMSO and may dissolve in DMSO, H2O, ethanol, or DMF. It is stored at -20°C protected from light.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Pterin-6-carboxylic acid has been evaluated in the context of its use as a research chemical. The compound is a folate precursor and a photodegradation product of folate. Its ability to augment ROS production and phototoxicity of UVA towards human cell lines suggests potential for phototoxic effects. As with all research chemicals, proper handling procedures including use of personal protective equipment are recommended. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile. The compound should be protected from light during storage.
|
| References | |
| Additional Infomation |
2-Amino-4-hydroxy-6-pteridinecarboxylic acid is an organic oxygen and organic nitrogen compound whose function is related to α-amino acids. Pterin-6-carboxylic acid has been reported in capsicum annuum var. annuum, and relevant data are available.
Pterin-6-carboxylic acid (CAS# 948-60-7) is also known as 2-amino-1,4-dihydro-4-oxopterin-6-carboxylic acid, 2-amino-4-hydroxy-6-pteridinecarboxylic acid, and 6-pteridinecarboxylic acid, 2-amino-3,4-dihydro-4-oxo. It has the molecular formula C7H5N5O3 and a molecular weight of 207.15. The compound serves as a precursor to folate, which plays a key role in cell growth, development and repair. Pterin-6-carboxylic acid has been investigated for its potential as a fluorescent dye. It is a photodegradation product of folate and augments ROS production and phototoxicity of UVA towards human cell lines. The compound has been reported in Capsicum annuum var. annuum. It is intended for research use only. |
| Molecular Formula |
C7H5N5O3
|
|---|---|
| Molecular Weight |
207.15
|
| Exact Mass |
207.039
|
| CAS # |
948-60-7
|
| PubChem CID |
135403803
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
2.16 g/cm3
|
| Boiling Point |
608.7ºC at 760 mmHg
|
| Melting Point |
360 °C
|
| Flash Point |
322ºC
|
| LogP |
-1.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
342
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CNC2C(C(N=C(N)N=2)=O)=N1)O
|
| InChi Key |
QABAUCFGPWONOG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H5N5O3/c8-7-11-4-3(5(13)12-7)10-2(1-9-4)6(14)15/h1H,(H,14,15)(H3,8,9,11,12,13)
|
| Chemical Name |
2-amino-4-oxo-3H-pteridine-6-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8274 mL | 24.1371 mL | 48.2742 mL | |
| 5 mM | 0.9655 mL | 4.8274 mL | 9.6548 mL | |
| 10 mM | 0.4827 mL | 2.4137 mL | 4.8274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
